Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Kalali

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Innovations in Clinical Neuroscience|April 26, 2021
INNOVATIONSCNS.COMAmir Kalali
Psychiatry (Edgmont (Pa. : Township))|September 19, 2009
Treatment of depression: an update on antidepressant monotherapy and combination therapySusan Lenderts, Amir Kalali
Innovations in Clinical Neuroscience|November 2, 2016
Digital Suicide Prevention: Can Technology Become a Game-changer?Arshya Vahabzadeh, Ned Sahin, Amir Kalali
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
Use of antipsychotics in childrenElisa Cascade, Amir Kalali, Robert Findling
The British Journal of Psychiatry : the Journal of Mental Science|October 3, 2006
Culture and assessment of manic symptomsPaul Mackin, Steven D Targum, Amir Kalali, et al.
Innovations in Clinical Neuroscience|January 27, 2015
Consensus recommendations on rater training and certification, Mark D West, David G Daniel, et al.
Psychopharmacology Bulletin|January 18, 2011
A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learnedAndrew J Cutler, Tram Tran-Johnson, Amir Kalali, et al.
Journal of Alzheimer'S Disease : JAD|March 28, 2022
Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial FailuresC Kwon Kim, Yin Rui Lee, Lynnett Ong, et al.
Journal of Clinical Psychopharmacology|March 23, 2002
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapineSteven G Potkin, Per T Thyrum, Gustavo Alva, et al.
International Clinical Psychopharmacology|March 11, 2010
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidoneCarla M Canuso, Augusto Grinspan, Amir Kalali, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Innovations in Clinical Neuroscience|April 26, 2021
INNOVATIONSCNS.COMAmir Kalali
Psychiatry (Edgmont (Pa. : Township))|September 19, 2009
Treatment of depression: an update on antidepressant monotherapy and combination therapySusan Lenderts, Amir Kalali
Innovations in Clinical Neuroscience|November 2, 2016
Digital Suicide Prevention: Can Technology Become a Game-changer?Arshya Vahabzadeh, Ned Sahin, Amir Kalali
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
Use of antipsychotics in childrenElisa Cascade, Amir Kalali, Robert Findling
The British Journal of Psychiatry : the Journal of Mental Science|October 3, 2006
Culture and assessment of manic symptomsPaul Mackin, Steven D Targum, Amir Kalali, et al.
Innovations in Clinical Neuroscience|January 27, 2015
Consensus recommendations on rater training and certification, Mark D West, David G Daniel, et al.
Psychopharmacology Bulletin|January 18, 2011
A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learnedAndrew J Cutler, Tram Tran-Johnson, Amir Kalali, et al.
Journal of Alzheimer'S Disease : JAD|March 28, 2022
Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial FailuresC Kwon Kim, Yin Rui Lee, Lynnett Ong, et al.
Journal of Clinical Psychopharmacology|March 23, 2002
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapineSteven G Potkin, Per T Thyrum, Gustavo Alva, et al.
International Clinical Psychopharmacology|March 11, 2010
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidoneCarla M Canuso, Augusto Grinspan, Amir Kalali, et al.
Pageof 2